Abstract:Adoptive cell transfer (ACT) with autologous tumor-reactive T-cells has recently shown great promise in the treatment of leukemias in clinical trials. However, effective control of solid tumors, in particular resistant, metastatic, or recurrent cancers, remain challenging. One of the major limitations is the rapid decline of T-cell function in the immunosuppressive tumor microenvironment. In order to maintain high numbers of viable antigen-specific cytotoxic T-cells in tumors, co-administration of supporting immunostimulant agents such as cytokines together with transferred cells is often employed. However, the high systemic doses of such agents needed to enhance T-cell functionality inside solid tumors can also result in serious side effects. Here, we developed a cell-responsive nanogel (NG) based on a novel carrier-free delivery strategy to effectively and specifically support adoptively transferred T-cells with recombinant cytokines such as interleukin-2 (IL-2) or interleukin-15 (IL-15). IL-2-Fc or an IL-15 superagonist (IL-15Sa) were chemically crosslinked with a disulfide linker to form these protein NGs, which were subsequently bound to and stably anchored on the plasma membrane of adoptively transferred T-cells ex vivo. These NGs had exceptionally high loading of cytokines (~70 wt%) and released native cytokine proteins in physiological condition in a sustained manner through breakdown of a degradable disulfide linker in response to the reduction activity at the plasma membrane surface of activated T-cells, and thus enabled continuous pseudo-autocrine stimulation of transferred CD8+ T-cells. In a mouse model of subcutaneous B16F10 melanoma tumors, adoptively transferred mouse pmel-1 CD8+ T-cells with optimized IL-15Sa-NGs showed markedly enhanced expansion and persistence in tumors and thus improved the anti-cancer efficacy. Quantification of transferred tumor-specific T-cells in tumors 7 days after transfer showed that surface-bound IL-15Sa-NGs resulted in ~16-fold more tumor-reactive T-cells compared to T-cells supported by an equivalent dose of soluble IL-15Sa administered systemically. Surface-bound IL-15Sa-NGs could be used to “backpack” T-cells with doses of cytokine that slowly released and maintained T-cell function over at least 2 weeks in vivo, while the same doses administered systemically as a bolus or repeated lower-dose injections were very toxic, eliciting systemic cytokine syndrome. These data demonstrate that T-cell surface-bound responsive cytokine-NGs provide autocrine support to the tumor-reactive T-cells to enhance efficacy of ACT therapy against solid tumors and safely administered potent adjuvant immunostimulants to donor T-cells. Citation Format: Li Tang, Yiran Zheng, Llian Mabardi, Darrell Irvine. T lymphocyte engineering with responsive cytokine nanogels for enhanced efficacy and safety of adoptive cell therapy for cancer. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr B53.

A Hybrid of B and T Lymphoblastic Cell Line Could Potentially Substitute Dendritic Cells to Efficiently Expand out Her-2/neu-specific Cytotoxic T Lymphocytes from Advanced Breast Cancer Patients in Vitro

Abstract 22: Development and characterization of human tumor specific cytotoxic lymphocytes for preclinical drug development

HER2-specific T Lymphocytes Kill Both Trastuzumab-Resistant and Trastuzumab-Sensitive Breast Cell Lines in Vitro

Large-Scale Expansion of Leukemia Specific CTLs Using Lysates-Pulsed Dendritic Cell and Low-Dose IL-2 for Adoptive Immunotherapy

Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells.

B-106 Development of Anti-Tumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells

Generation of Tumor-Specific Cytotoxic T Cells From Blood via In Vitro Expansion Using Autologous Dendritic Cells Pulsed With Neoantigen-Coupled Microbeads

T Cells Expressing a HER2-specific Chimeric Antigen Receptor As Treatment for Breast Cancer.

Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response.

Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors

Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy

Abstract 4056: Intratumoral delivery of autologous tumor antigen specific CD4 Th1 cells combined with dendritic cells eradicates HER2 mammary carcinoma

Enhanced Cytotoxicity And Underlying Mechanism Of Ex Vivo Expanded Natural Killer Cells Against Breast Cancer Cells

Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.

Generation and Characterization of Antitumor Infiltrating Lymphocytes from Patients with Breast Cancer for Adoptive Cell Transfer Therapy

Large-scale culture system of human CD4+ helper/killer T cells for the application to adoptive tumour immunotherapy

T Lymphocyte Engineering With Responsive Cytokine Nanogels For Enhanced Efficacy And Safety Of Adoptive Cell Therapy For Cancer

Induction of Specific Cytolytic T Lymphocytes Using Fusions of Hepatocellular Carcinoma (HCC) Patient-Derived Dendritic Cells and Allogeneic HCC Cell Line.

Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast Cancer Cells Expressing Human Epidermal Growth Factor Receptor-2

HER2 As a Promising Target for Cytotoxicity T Cells in Human Melanoma Therapy

Allo-Restricted Ctls Generated By Coculturing Of Pbls And Autologous Monocytes Loaded With Allogeneic Peptide/Hla/Igg1-Fc Fusion Protein